Patents by Inventor Pascal Furet

Pascal Furet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060211747
    Abstract: The present invention relates to methods of searching/screening for compounds which inhibit the activity of the ubiquitin conjugating enzyme Cdc34 in a zinc-mediated manner, to compounds obtainable by such a method, to a method of treating mammalian subjects with such compounds, to pharmaceutical compositions containing such compounds, to the use of such compounds for the treatment of diseases which respond to an inhibition of the activity of Cdc34 such as proliferative diseases, especially tumor diseases, and to the use of such compounds for the preparation of such pharmaceutical compositions for the treatment of such diseases.
    Type: Application
    Filed: September 14, 2005
    Publication date: September 21, 2006
    Inventors: Pascal Furet, Francesco Hofmann, Edgar Jacoby, Joseph Schoepfer
  • Publication number: 20060205673
    Abstract: The invention relates to compounds of formula I wherein the substituents and symbols are defined as indicated in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: May 15, 2006
    Publication date: September 14, 2006
    Inventors: Pascal Furet, Carlos Garcia-Echeverria, Patricia Imbach, Marc Lang, Johann Zimmermann
  • Patent number: 7091346
    Abstract: 2-Amino-6-anilino-purine derivatives of the formula 1 in which the symbols are as defined in claim 1 are described. These compounds inhibit p34cdc2/cyclin Bcdc13 kinase and can be used for treatment of hyperproliferative diseases, for example tumour diseases.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: August 15, 2006
    Assignee: Novartis AG
    Inventors: Jürg Zimmermann, Hans-Georg Capraro, Patricia Imbach, Pascal Furet
  • Patent number: 7091224
    Abstract: The invention relates to anthranilic acid amide derivatives of formula (I), wherein R1 represents H or lower alkyl, R2 represents H or lower alkyl, R3 represents perfluoro lower alkyl, and X is O or S, or an N-oxide or a tautomer thereof, to salts of such anthranilic acid amides, their N-oxides and their tautomers; processes for the preparation thereof, the application thereof for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age—related macular degeneration; a method for the treatment of such a disease in animals, especially in humans, and the use of such a compound—alone or in combination with one or more other pharmaceutically active compounds—for the manufacture of a pharmaceutical preparation for the treatment of a neoplastic disease, of retinopathy or age-related macular degeneration.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: August 15, 2006
    Assignee: Novartis AG
    Inventors: Guido Bold, Pascal Furet, Paul W Manley
  • Publication number: 20060178409
    Abstract: The invention relates to anthranilic acid amide derivatives of formula I, wherein R1 represents H or lower alkyl, R2 represents H or lower alkyl, R3 represents perfluoro lower alkyl, and X is O or S, or an N-oxide or a tautomer thereof, to salts of such anthranilic acid amides, their N-oxides and their tautomers; processes for the preparation thereof, the application thereof for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration; a method for the treatment of such a disease in animals, especially in humans, and the use of such a compound—alone or in combination with one or more other pharmaceutically active compounds—for the manufacture of a pharmaceutical preparation for the treatment of a neoplastic disease, of retinopathy or age-related macular degeneration.
    Type: Application
    Filed: March 14, 2006
    Publication date: August 10, 2006
    Inventors: Guido Bold, Pascal Furet, Paul Manley
  • Patent number: 7083983
    Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.
    Type: Grant
    Filed: July 4, 1997
    Date of Patent: August 1, 2006
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: David Philip Lane, Volker Böttger, Angelika Böttger, Steven Michael Picksley, Heinz-Kurt Hochkeppel, Carlos Garcia-Echeverria, Patrick Chène, Pascal Furet
  • Publication number: 20060167015
    Abstract: The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
    Type: Application
    Filed: July 4, 2003
    Publication date: July 27, 2006
    Inventors: Werner Breitenstein, Pascal Furet, Sandra Jacob, Paul Manley
  • Publication number: 20060142577
    Abstract: The invention relates to novel substituted N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidinamine derivatives, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, and a method for the treatment of such a disease.
    Type: Application
    Filed: September 26, 2003
    Publication date: June 29, 2006
    Inventors: Paul Manley, Werner Breitenstein, Sandra Jacob, Pascal Furet
  • Patent number: 7067543
    Abstract: The invention relates to anthranilic acid amide derivatives of formula (I), wherein Ar is represented by the subformula (Ia), wherein Ra represents H or lower alkyl, and R1 represents H or perfluoro lower alkyl, R2 represents H, halogen, C2–C7alkyl, C2–C7alkenyl or lower aklynyl; or Ar is represented by the subformula (Ib) and R1 represents perfluoro lower alkyl, and R2 represents bromo, iodo, C2–C7alkyl, C2–C7alkenyl or lower alkynyl, or R1 represents H, and R2 represents fluoro, bromo, iodo, ethyl, C5–C7alkyl, C2–C7alkenyl or lower alkynyl; to N-oxides and tautomers thereof, and to salts of such anthranilic acid amides, its N-oxides and tautomers; to processes for their preparation; to their application in the treatment of the human or animal body, to the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration; to a method for the treatment of
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: June 27, 2006
    Assignee: Novartis AG
    Inventors: Guido Bold, Pascal Furet, Paul W Manley
  • Publication number: 20060128734
    Abstract: The invention relates to the use of diaryl urea derivatives in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising diaryl urea derivatives for the treatment of said diseases, diaryl urea derivatives for use in the treatment of said diseases, novel diaryl urea derivatives, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.
    Type: Application
    Filed: May 28, 2003
    Publication date: June 15, 2006
    Inventors: Andreas Floersheimer, Pascal Furet
  • Publication number: 20060128684
    Abstract: The present invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds.
    Type: Application
    Filed: December 11, 2003
    Publication date: June 15, 2006
    Inventors: Guido Bold, Pascal Furet, Paul Manley
  • Publication number: 20060106027
    Abstract: The invention relates to phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives—alone or in combination with one or more other pharmaceutically active compounds—for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.
    Type: Application
    Filed: July 8, 2003
    Publication date: May 18, 2006
    Inventors: Pascal Furet, Patricia Imbach, Timothy Ramsey, Achim Schlapbach, Dieter Scholz, Giorgio Caravatti
  • Publication number: 20060074112
    Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y?SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each, other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
    Type: Application
    Filed: October 20, 2005
    Publication date: April 6, 2006
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul Manley, Jeanette Wood, Stefano Ferrari, Francesco Hofmann, Jurgen Mestan, Andreas Huth, Martin Kruger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch
  • Publication number: 20060058324
    Abstract: The invention relates to new 4-amino-5-phenyl-7-cyclohexyl-pyrrolo[2,3-d]pyrimidine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof, alone or in combination with one or more other pharmaceutically active compounds, for the treatment of a disease, especially a proliferative disease, such as a tumour disease, a method for the treatment of such diseases in mammals, especially in humans, and the use of such a compound, alone or in combination with one or more other pharmaceutically active compounds, for the preparation of a pharmaceutical composition (medicament) for the treatment especially of a proliferative disease, such as a tumour.
    Type: Application
    Filed: November 11, 2003
    Publication date: March 16, 2006
    Inventors: Hans-Georg Capraro, Pascal Furet, Carlos Garcia-Echeverria
  • Patent number: 7002022
    Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R2 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y=SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: February 21, 2006
    Assignees: Novartis AG, Schering Aktiengesellschaft
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch
  • Publication number: 20060035897
    Abstract: The invention relates to trifluoromethyl substituted benzamide compounds of the formula I, pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases, especially of ephrin receptor kinases, and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative disease, methods of treatment comprising administering the compounds, especially of therapeutic and prophylactic treatment, methods for the manufacture of the compounds and novel intermediates and partial steps for their synthesis.
    Type: Application
    Filed: August 10, 2005
    Publication date: February 16, 2006
    Inventors: Giorgio Caravatti, Pascal Furet, Patricia Imbach, Georg Martiny-Baron, Lawrence Perez, Tao Sheng
  • Publication number: 20050245562
    Abstract: The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.
    Type: Application
    Filed: May 20, 2003
    Publication date: November 3, 2005
    Inventors: Carlos Garcia-Echeverria, Hans-Georg Capraro, Pascal Furet
  • Publication number: 20050239716
    Abstract: The present invention relates to compounds of formula I wherein the substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical preparations comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: June 30, 2005
    Publication date: October 27, 2005
    Inventors: Pascal Furet, Vito Guagnano, Patricia Imbach, Marc Lang
  • Publication number: 20050222171
    Abstract: The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.
    Type: Application
    Filed: January 20, 2005
    Publication date: October 6, 2005
    Inventors: Guido Bold, Andreas Floersheimer, Pascal Furet, Patricia Imbach, Keiichi Masuya, Joseph Schoepfer
  • Patent number: 6933290
    Abstract: Disclosed are derivatives of 2-{[N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid, processes for the preparation of such compounds, pharmaceutical preparations, and the use of such derivatives in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: August 23, 2005
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Patricia Imbach, Marc Lang